000162787 001__ 162787
000162787 005__ 20240320115515.0
000162787 0247_ $$2pmc$$apmc:PMC8739306
000162787 0247_ $$2doi$$a10.1007/s00415-021-10866-2
000162787 0247_ $$2pmid$$apmid:34718884
000162787 0247_ $$2ISSN$$a0012-1037
000162787 0247_ $$2ISSN$$a0340-5354
000162787 0247_ $$2ISSN$$a0939-1517
000162787 0247_ $$2ISSN$$a1432-1459
000162787 0247_ $$2ISSN$$a1619-800X
000162787 0247_ $$2ISSN$$a0367-004x
000162787 0247_ $$2ISSN$$a0367-004X
000162787 037__ $$aDZNE-2021-01442
000162787 041__ $$aEnglish
000162787 082__ $$a610
000162787 1001_ $$aTütüncü, Serdar$$b0
000162787 245__ $$aOff-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry.
000162787 260__ $$aBerlin$$bSpringer$$c2022
000162787 3367_ $$2DRIVER$$aarticle
000162787 3367_ $$2DataCite$$aOutput Types/Journal article
000162787 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655200190_926
000162787 3367_ $$2BibTeX$$aARTICLE
000162787 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162787 3367_ $$00$$2EndNote$$aJournal Article
000162787 500__ $$aISSN 1432-1459 not unique: **2 hits**. (CC BY)
000162787 520__ $$aWe aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke.The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke.At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01].At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge.NCT02306824.
000162787 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162787 542__ $$2Crossref$$i2021-10-31$$uhttps://creativecommons.org/licenses/by/4.0
000162787 542__ $$2Crossref$$i2021-10-31$$uhttps://creativecommons.org/licenses/by/4.0
000162787 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162787 650_7 $$2Other$$aAtrial fibrillation
000162787 650_7 $$2Other$$aIschemic stroke
000162787 650_7 $$2Other$$aNOAC
000162787 650_7 $$2Other$$aUnder-dosing
000162787 650_2 $$2MeSH$$aAdministration, Oral
000162787 650_2 $$2MeSH$$aAged, 80 and over
000162787 650_2 $$2MeSH$$aAnticoagulants: therapeutic use
000162787 650_2 $$2MeSH$$aAtrial Fibrillation: complications
000162787 650_2 $$2MeSH$$aAtrial Fibrillation: drug therapy
000162787 650_2 $$2MeSH$$aBerlin
000162787 650_2 $$2MeSH$$aBrain Ischemia: complications
000162787 650_2 $$2MeSH$$aBrain Ischemia: drug therapy
000162787 650_2 $$2MeSH$$aHumans
000162787 650_2 $$2MeSH$$aOff-Label Use
000162787 650_2 $$2MeSH$$aProspective Studies
000162787 650_2 $$2MeSH$$aRegistries
000162787 650_2 $$2MeSH$$aStroke: complications
000162787 650_2 $$2MeSH$$aStroke: drug therapy
000162787 7001_ $$aOlma, Manuel$$b1
000162787 7001_ $$aKunze, Claudia$$b2
000162787 7001_ $$aDietzel, Joanna$$b3
000162787 7001_ $$aSchurig, Johannes$$b4
000162787 7001_ $$aFiessler, Cornelia$$b5
000162787 7001_ $$aMalsch, Carolin$$b6
000162787 7001_ $$aHaas, Tobias Eberhard$$b7
000162787 7001_ $$aDimitrijeski, Boris$$b8
000162787 7001_ $$aDoehner, Wolfram$$b9
000162787 7001_ $$aHagemann, Georg$$b10
000162787 7001_ $$aHamilton, Frank$$b11
000162787 7001_ $$aHonermann, Martin$$b12
000162787 7001_ $$aJungehulsing, Gerhard Jan$$b13
000162787 7001_ $$aKauert, Andreas$$b14
000162787 7001_ $$aKoennecke, Hans-Christian$$b15
000162787 7001_ $$aMackert, Bruno-Marcel$$b16
000162787 7001_ $$aNabavi, Darius$$b17
000162787 7001_ $$0P:(DE-HGF)0$$aNolte, Christian H$$b18
000162787 7001_ $$aReis, Joschua Mirko$$b19
000162787 7001_ $$aSchmehl, Ingo$$b20
000162787 7001_ $$aSparenberg, Paul$$b21
000162787 7001_ $$aStingele, Robert$$b22
000162787 7001_ $$aVölzke, Enrico$$b23
000162787 7001_ $$aWaldschmidt, Carolin$$b24
000162787 7001_ $$aZeise-Wehry, Daniel$$b25
000162787 7001_ $$aHeuschmann, Peter U$$b26
000162787 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b27$$udzne
000162787 7001_ $$aHaeusler, Karl Georg$$b28
000162787 77318 $$2Crossref$$3journal-article$$a10.1007/s00415-021-10866-2$$bSpringer Science and Business Media LLC$$d2021-10-31$$n1$$p470-480$$tJournal of Neurology$$v269$$x0340-5354$$y2021
000162787 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-021-10866-2$$n1$$p470-480$$tJournal of neurology$$v269$$x0340-5354$$y2021
000162787 8564_ $$uhttps://pub.dzne.de/record/162787/files/DZNE-2021-01442.pdf$$yOpenAccess
000162787 8564_ $$uhttps://pub.dzne.de/record/162787/files/DZNE-2021-01442.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162787 909CO $$ooai:pub.dzne.de:162787$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162787 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000162787 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162787 9141_ $$y2022
000162787 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000162787 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000162787 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2021$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162787 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2021$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000162787 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-12$$wger
000162787 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000162787 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lCoordinator of Clinical Research$$x0
000162787 980__ $$ajournal
000162787 980__ $$aVDB
000162787 980__ $$aUNRESTRICTED
000162787 980__ $$aI:(DE-2719)1811005
000162787 9801_ $$aFullTexts
000162787 999C5 $$1SJ Connolly$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa0905561$$p1139 -$$tN Engl J Med$$uConnolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151$$v361$$y2009
000162787 999C5 $$1MR Patel$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1009638$$p883 -$$tN Engl J Med$$uPatel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891$$v365$$y2011
000162787 999C5 $$1CB Granger$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1107039$$p981 -$$tN Engl J Med$$uGranger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992$$v365$$y2011
000162787 999C5 $$1RP Giugliano$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1310907$$p2093 -$$tN Engl J Med$$uGiugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104$$v369$$y2013
000162787 999C5 $$1Y Xian$$2Crossref$$9-- missing cx lookup --$$a10.1001/jamaneurol.2019.2099$$p1192 -$$tJAMA Neurol$$uXian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL et al (2019) Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol 76(10):1192–1202$$v76$$y2019
000162787 999C5 $$2Crossref$$uHindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE et al (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J
000162787 999C5 $$1CT January$$2Crossref$$9-- missing cx lookup --$$a10.1161/CIR.0000000000000665$$pe125 -$$tCirculation$$uJanuary CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 140(2):e125–e151$$v140$$y2019
000162787 999C5 $$2Crossref$$u(AWMF) AdWMF: S3-Leitlinie Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke
000162787 999C5 $$1KG Haeusler$$2Crossref$$9-- missing cx lookup --$$a10.1093/europace/euz199$$p1621 -$$tEuropace$$uHaeusler KG, Tütüncü S, Kunze C, Schurig J, Malsch C, Harder J, Wiedmann S, Dimitrijeski B, Ebinger M, Hagemann G et al (2019) Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace 21(11):1621–1632$$v21$$y2019
000162787 999C5 $$1C Tanislav$$2Crossref$$9-- missing cx lookup --$$a10.1177/1747493017733928$$p308 -$$tInt J Stroke$$uTanislav C, Allendörfer J, Pfeilschifter W, Fuest S, Stein M, Meyer M, Reuter I, Kaps M, Misselwitz B (2018) One decade of oral anticoagulation in stroke patients: results from a large country-wide hospital-based registry. Int J Stroke 13(3):308–312$$v13$$y2018
000162787 999C5 $$1SH Hohnloser$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00392-019-01437-7$$p1042 -$$tClin Res Cardiol$$uHohnloser SH, Basic E, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol 108(9):1042–1052$$v108$$y2019
000162787 999C5 $$1BA Steinberg$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ahj.2017.08.011$$p132 -$$tAm Heart J$$uSteinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S et al (2017) International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 194:132–140$$v194$$y2017
000162787 999C5 $$1J Steffel$$2Crossref$$9-- missing cx lookup --$$a10.1093/eurheartj/ehy136$$p1330 -$$tEur Heart J$$uSteffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393$$v39$$y2018
000162787 999C5 $$1BA Steinberg$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jacc.2016.09.966$$p2597 -$$tJ Am Coll Cardiol$$uSteinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J et al (2016) Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 68(24):2597–2604$$v68$$y2016
000162787 999C5 $$1BA Steinberg$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.tcm.2017.06.012$$p567 -$$tTrends Cardiovasc Med$$uSteinberg BA, Washam JB (2017) Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends Cardiovasc Med 27(8):567–572$$v27$$y2017
000162787 999C5 $$1M Miyazaki$$2Crossref$$9-- missing cx lookup --$$a10.1186/s40780-020-0157-z$$p2 -$$tJ Pharm Health Care Sci$$uMiyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, Tokura K, Jimi S, Okamura K, Adachi S et al (2020) Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci 6:2$$v6$$y2020
000162787 999C5 $$1K Ablefoni$$2Crossref$$9-- missing cx lookup --$$a10.1002/clc.23235$$p873 -$$tClin Cardiol$$uAblefoni K, Buchholz A, Ueberham L, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A (2019) Initial rivaroxaban dosing in patients with atrial fibrillation. Clin Cardiol 42(10):873–880$$v42$$y2019
000162787 999C5 $$1KL Wang$$2Crossref$$9-- missing cx lookup --$$a10.1093/eurheartj/ehy802$$p1492 -$$tEur Heart J$$uWang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP (2019) Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J 40(19):1492–1500$$v40$$y2019
000162787 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/JAHA.117.007633$$uSteinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV et al (2018) Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 7(4)
000162787 999C5 $$1P Amarenco$$2Crossref$$9-- missing cx lookup --$$a10.1093/ehjcvp/pvy041$$p70 -$$tEur Heart J Cardiovasc Pharmacother$$uAmarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ (2019) Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother 5(2):70–79$$v5$$y2019
000162787 999C5 $$1S Hatano$$2Crossref$$uHatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54(5):541–553$$y1976
000162787 999C5 $$1T Brott$$2Crossref$$9-- missing cx lookup --$$a10.1161/01.STR.20.7.864$$p864 -$$tStroke$$uBrott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20(7):864–870$$v20$$y1989
000162787 999C5 $$1JC van Swieten$$2Crossref$$9-- missing cx lookup --$$a10.1161/01.STR.19.5.604$$p604 -$$tStroke$$uvan Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607$$v19$$y1988
000162787 999C5 $$2Crossref$$uIngelheim B (2019) Fachinformation Pradaxa 150 mg Hartkapseln
000162787 999C5 $$1CT Ruff$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(13)62343-0$$p955 -$$tLancet$$uRuff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962$$v383$$y2014
000162787 999C5 $$1S Haas$$2Crossref$$uHaas S (2015) im Namen des G-AFSC: [GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany]. Dtsch Med Wochenschr 140(Suppl 1):S13-14$$y2015
000162787 999C5 $$1MV Huisman$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.amjmed.2015.07.013$$p1306 -$$tAm J Med$$uHuisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A et al (2015) Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry Phase II. Am J Med 128(12):1306-1313.e1301$$v128$$y2015
000162787 999C5 $$1Y Okumura$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.joa.2016.11.003$$p289 -$$tJ Arrhythm$$uOkumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K et al (2017) Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm 33(4):289–296$$v33$$y2017
000162787 999C5 $$1JS Paikin$$2Crossref$$9-- missing cx lookup --$$a10.1586/erc.11.21$$p279 -$$tExpert Rev Cardiovasc Ther$$uPaikin JS, Haroun MJ, Eikelboom JW (2011) Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther 9(3):279–286$$v9$$y2011
000162787 999C5 $$1G Boriani$$2Crossref$$9-- missing cx lookup --$$a10.1093/europace/euz032$$p1013 -$$tEuropace$$uBoriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L et al (2019) Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 21(7):1013–1022$$v21$$y2019
000162787 999C5 $$1K Haas$$2Crossref$$9-- missing cx lookup --$$a10.1177/2396987318812644$$p181 -$$tEur Stroke J$$uHaas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R (2019) Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J 4(2):181–188$$v4$$y2019
000162787 999C5 $$1S Stoll$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00415-020-09795-3$$p2007 -$$tJ Neurol$$uStoll S, Macha K, Marsch A, Gerner ST, Siedler G, Fröhlich K, Volbers B, Strasser EF, Schwab S, Kallmünzer B (2020) Ischemic stroke and dose adjustment of oral factor Xa inhibitors in patients with atrial fibrillation. J Neurol 267(7):2007–2012$$v267$$y2020
000162787 999C5 $$1S Hellwig$$2Crossref$$9-- missing cx lookup --$$a10.1093/europace/eux087$$p569 -$$tEP Europace$$uHellwig S, Grittner U, Audebert H, Endres M, Haeusler KG (2018) Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. EP Europace 20(4):569–574$$v20$$y2018